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Photo-responsive species are used to manipulate intracellular biochemical pathways, light-
sensitive nanoparticles employed to site-selectively deliver cytotoxic agents, and photo-
initiated hydrogels applied as biomaterial replacements.[1] However, the application of these
molecular entities is dependent upon short wavelengths (<450 nm), which inflict biological
damage and are unable to take advantage of the optical window of tissue (600 – 1300 nm).[2]
Furthermore, the narrow wavelength-response range limits the ability to design a family of
photo-activatable species that can be orthogonally triggered at distinct wavelengths.[3] We
recently reported expansion of the photo-responsive toolkit to green light (approximately
560 nm),[4] however these compounds do not absorb light that falls within the optical
window of tissue. With these challenges in mind, we report herein wavelength tunable
photo-responsive species based on the vitamin B12 cobalamin ring framework. These
species are easily encoded, using commercially available fluorophores,[5] to respond to
specific wavelengths throughout the visible spectrum and into the near IR.
A fluorescence increase is observed upon photolysis of a 5-carboxytetramethyl-rhodamine
(TAMRA)-substituted cobalamin (Cbl-1) due to the ability of cobalamin to quench the
fluorescence of attached fluorophores (Figure 1).[4, 6] The latter is a likely consequence of
contact quenching between the fluorophore and the corrin ring system.[6b] Contact
quenching, unlike fluorescence energy resonance transfer, does not require an overlap
between the emission and absorption wavelengths of the fluorophore and quencher,
respectively, for energy transfer to transpire. Given the fact that the Co-alkyl bond is weak
(<30 kcal/mol),[7] it occurred to us that fluorophores excited at wavelengths beyond that
absorbed by cobalamin (>560 nm) could transfer their excited state energy to the corrin ring
and thus promote Co-C bond scission (Fig. 1). Indeed, Cbl-1 suffers a photolysis conversion
rate (8.0 ± 0.4 × 10−3 s−1) twice that of its non-fluorophore-containing counterparts, MeCbl
and Cbl-2 (3.8 ± 0.2 × 10−3 s−1 and 4.2 ± 0.2 × 10−3 s−1, respectively) (Figs. 1, S1 – S4),
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suggesting that excitation of an appended fluorophore could play a role in promoting
photocleavage of the Co-C bond.
Several fluorophores were appended to the alkylcobalamin framework, all with excitation
wavelengths longer than that absorbed by the corrin ring (Cbl-2 – Cbl-6). A number of
features are apparent from the results presented in Table 1. First, illumination at the corrin
absorption wavelength (546 nm) completely converts all derivatives to their photolyzed
products if sufficient light exposure is applied (25 min under the conditions described in the
Supplementary Information). However, at a much shorter illumination time (5 min), Cbl-1 is
more completely photolyzed at 546 nm than its counterparts, presumably due to the
significant TAMRA absorbance in this region (ε = 90,000 cm−1 M−1). Second, all
compounds undergo photolysis at their excitation wavelengths, even at those wavelengths
that are far beyond the absorbance of the corrin ring. The cobalamin-SulfoCy5 conjugate
Cbl-3 (λex 650 nm, λem 660 nm), when illuminated at 646 ± 10 nm, is photocleaved to
hydroxocobalamin (B12a) and SulfoCy5 products as assessed by UV-Vis (Fig. S5) and
LC/MS (Table S2, Scheme S7). The Atto725 (Cbl-4, λex 730 nm, λem 750 nm) and
Dylight800 (Cbl-5, λex 775 nm, λem 794 nm) conjugates likewise undergo photolysis at
wavelengths absorbed by the appended fluorophores, namely 730 ± 10 and 780 ± 10 nm,
respectively (Figs. S6 – S7, Tables S3 and S4). Third, all cobalamin-fluorophore conjugates
are stable in the dark. Fourth, exposure of these conjugates to wavelengths that they do not
absorb has no effect on their structural integrity. The TAMRA derivative, Cbl-1, is stable at
646 nm and longer (Table 1). Cbl-3, with an appended fluorophore that absorbs 646 nm
light, is unaffected by 727 and 777 nm illumination.
The results in Table 1 suggest that it should be possible to selectively photolyze specific
compounds from a mixture of cobalamin-substituted derivatives by employing the
appropriate illumination sequence and/or choice of wavelengths. Due to the slight photolysis
observed for Cbl-4 at 777 nm, the latter was replaced with the Alexa700-appended
conjugate Cbl-6, which lacks an absorption band at 777 nm. Only Cbl-5 photolysis occurs
when illuminating a mixture of Cbl-5, Cbl-6, Cbl-3, Cbl-1 at 777 nm [Fig. 2(a)].
Subsequent exposure of the mixture to 700 nm elicits the conversion of Cbl-6 to its
photoproducts without affecting Cbl-3 or Cbl-1 [Fig. 2(b)]. A final sequential illumination
at 646 and 546 nm [Figs. 2(c) and 2(d)] furnishes the stepwise photolysis of Cbl-3 and
Cbl-1, respectively. As expected, 546 nm illumination of a mixture of these Cbl derivatives
failed to furnish selective photolysis, which is predictable based on the data in Table 1. By
contrast, since Cbl-3 and Cbl-5 are photochemically distinct at 646 nm and 777 nm (Table
1, Fig. S19), they can be individually photo-manipulated without the need to resort to a
specific illumination sequence (Fig. S20). The more than 200 nm bandwidth of the
cobalamin-fluorophore conjugates in Table 1 furnishes the spectral range upon which
specific compounds in a mixture can be orthogonally communicated with and acted upon.
Indeed, since the dissociation energy of the Co-C bond is estimated to be less than 30 kcal/
mol,[7] it may be feasible to sensitize bond cleavage up to and beyond 1000 nm.
Fluorophores appended to the ribose 5′-OH of alkylcobalamins also promote photocleavage
of the Co-alkyl linkage (Figure 1, AdoCbl-1 – AdoCbl-4). Our initial studies employed
coenzyme B12 (AdoCbl) derivatives since Schwartz and Frey previously identified the
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adenosine products of photolysis.[8] LC/MS confirmed that 546 nm illumination of AdoCbl
(no fluorophore) and AdoCbl-1 (TAMRA) generates the expected products (Tables S6 –
S7). Furthermore, both AdoCbl and AdoCbl-1 are resistant to photolysis at wavelengths
beyond 600 nm. In a fashion analogous to the behavior displayed by the Cbl-3 – Cbl-6
series, the fluorophore-substituted AdoCbl-2 (SulfoCy5), AdoCbl-3 (Atto725), and
AdoCbl-4 (Dylinght800) derivatives produce the anticipated adenosine products at the
wavelengths absorbed by their appended fluorophores (Tables S8 – S10). In short,
photolytic release of compounds attached to the Co of cobalamin is tunable, in a predictable
fashion, using commercially available fluorophores appended to either the ribose ring or the
metal ligand.
Light-responsive small molecules are commonly prepared by covalently modifying a
functional group essential for biological activity with a photocleavable moiety,[1] whereas
genetically expressed light-responsive proteins are typically designed by engineering a link
between light-induced conformational changes and biochemical activities.[9] Cobalamins
offer a potentially attractive alternative since conjugates of the latter appear to be retained by
endosomes.[10] There has been a herculean effort to create delivery strategies that avoid
these organelles since endosomally-embedded bioactive species are unable to interact with
their intracellular targets. This liability represents an opportunity for cobalamin conjugates:
cell permeable bioactive species can potentially be endosomally sequestered, which should
preclude their action until released by light. With this in mind, the Bodipy650 derivative
Cbl-Bod was prepared (Fig. 3, Schemes S2 – S4). Bodipy650 is cytotoxic by virtue of a
mitochondria-targeting based mechanism.[11] However, the corresponding Cbl-Bod
conjugate, unlike Bodipy650, is endosomal as judged by an endosomal marker (Pearson’s
coefficient 0.89; Fig. 4). Furthermore, it remains endosomally sequestered even after 5 h in
the dark. Illumination of cells containing Cbl-Bod at 650 nm furnishes a fluorescent
increase (230 ± 6%, Figs. S26 – S27) similar to that observed in the spectrofluorometer (220
± 30%), signaling liberation of the Bodipy650 from the quenching effect of the cobalamin.
Under these conditions, Bodipy650 is simultaneously transferred from endosomes to
mitochondria, as assessed by the mitochondrial marker, Mitotracker Green (Pearson’s
coefficient: 0.81). This supports the notion that endosomal capture of cobalamin derivatives
can be exploited as a means to sequester cell-permeable bioactive agents from their
intracellular targets. As an aside, it should be feasible to employ non-endosomal strategies
for sequestration and release of light sensitive cobalamin derivatives as well.[12]
We examined the use of light to control the activity of a cAMP-dependent protein kinase
(PKA) signaling pathway. A cobalamin-appended analog of cAMP, Cbl-cAMP, was
prepared (Fig. 3, Scheme S10). cAMP-induced activation of PKA is known to promote
dramatic morphological changes in cells, including loss of stress fibers and cell-
rounding.[13] In the absence of illumination, Cbl-cAMP has no effect on the morphology of
REF52 cells. Upon illumination in the presence of Cbl-cAMP, REF52 cells undergo the
expected loss of their stress fiber content as well as cell shrinking and rounding (Fig. 5). In
addition, an 8-substituted acetylated-cAMP analog (Ac-cAMP, Scheme S9) was prepared
and used as a control. Both Ac-cAMP and a commercially available cell-permeable cAMP
analog [8-(4-chloro-phenylthio)-2’-O-methyladenosine-3’,5’-cyclic monophosphate; CPT-
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cAMP] are active in the absence of light, producing morphological effects on REF52 cells
analogous to those displayed by Cbl-cAMP upon illumination (Fig. S28). These results
demonstrate that the cobalamin in Cbl-cAMP precludes cytosolic penetration by an
appended cAMP derivative (cf. Ac-cAMP is cell permeable) and that illumination releases
cAMP from its cobalamin constraint.
There is significant interest in the use of light to site-selectively deliver therapeutic agents in
vivo. For example, in the arena of chemotherapy, strategies that limit cytotoxicity to targeted
regions offer the promise of reduced side effects and the application of otherwise too-toxic-
to-use agents. Doxorubicin highlights this need since this valuable anticancer agent displays
severe cardiotoxicity.[14] We examined the cytotoxicity of the cobalamin-doxorubicin
conjugate Cbl-Dox (Fig. 3, Scheme S11) in HeLa cells, illumination times (Fig. 6). Light-
only treatment, or Cbl-Dox exposure in the absence of photolysis, has no effect on cell
viability. In addition, Cbl-Dox exposure in the absence of illumination is completely
innocuous. By contrast, Cbl-Dox exposure with increasing illumination time furnishes a
light dose-dependent increase in cell death that ultimately recapitulates that produced by
doxorubicin alone.
The chemistry of photo-responsive agents has been, for the most part, limited to long UV/
short visible wavelengths (300 – 450 nm).[1,3,4] This narrow region of the electromagnetic
spectrum (a) lacks the desired tissue-penetrating depth displayed by 650 – 1000 nm
wavelengths, (b) inflicts bio-molecular damage which can have undesirable short and long
term in vivo consequences, and (c) can support only a limited number of orthogonal
wavelength-responsive agents. Although the corrin ring of B12 is unable to efficiently
absorb light beyond 550 nm, we found that commercially available fluorophores can be used
as antennas to capture long wavelength light, which promotes scission of the Co-C bond at
wavelengths up to 800 nm. Indeed, since the dissociation energy of this bond is estimated to
be less than 30 kcal/mol,[7] it may be feasible to sensitize bond cleavage up to and beyond
1000 nm. In summary, the ability to control the molecular properties of bioactive species
with long visible and near-IR light has implications in drug delivery, material fabrication,
nanotechnology, and the spatiotemporal control of cellular behavior.
Experimental Section
See the online Supporting Information for Materials and Methods, Tables, additional
Figures, and Schemes
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Methylcobalamin (MeCbl) and cobalamin-fluorophore conjugates: Cbl-1 (TAMRA), Cbl-2
(Acetyl), Cbl-3 (SulfoCy5), Cbl-4 (Atto725), Cbl-5 (Dylight 800), Cbl-6 (Alexa700),
AdoCbl-1 (TAMRA), AdoCbl-2 (SulfoCy5), AdoCbl-3 (Atto725), AdoCbl-4 (Dylight800).
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Selective photolysis of individual cobalamin-conjugates from a mixture using serial
illumination [(a) 777 nm → (b) 700 nm → (c) 646 nm → (d) 546 nm] sequentially
photolyzes Cbl-5, Cbl-6, Cbl-3, and Cbl-1, respectively.
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The Bodipy650-, cAMP-, and doxorubicin-cobalamin conjugates Cbl-Bod, Cbl-cAMP, and
Cbl-Dox, respectively.
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Red light induced translocation of Bodipy 650 in HeLa cells. (a) Cbl-Bod before photolysis
(b) Rhodamine B-dextran endosomal marker (c) overlay of (a) and (b). (d) Cbl-Bod after
photolysis (e) MitoTracker Green mitochondria marker (f) overlay of (d) and (e).
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Light-dependent Cbl-cAMP-mediated rearrangement of actin cytoskeleton in rat embryonic
fibroblasts (REF-52). Ref-52s were exposed to Cbl-cAMP, illuminated at 530 nm, and
stained with Dylight 488-phalloidin to visualize the actin stress fibers. (a) No treatment,
media alone (b) CPT-cAMP as a positive control (c) Cbl-cAMP, no illumination (d) Cbl-
cAMP with illumination. Images are representative of 10 – 20 cells.
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Light-induced release of doxorubicin from Cbl-Dox induces apoptosis of HeLa cells. Cells
were loaded with 10 µM Cbl-Dox and illuminated for 30, 45, and 75 s at 530 nm. Cell
viability was assessed, after 24 h, via an MTS assay (absorbance measured at 520 nm and
normalized to the untreated control). The data shown are the average of three experiments ±
SEM.
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